HLS Therapeutics Inc. (OTCMKTS:HLTRF) was the recipient of a significant increase in short interest in the month of August. As of August 31st, there was short interest totalling 23,200 shares, an increase of 19.0% from the August 15th total of 19,500 shares. Based on an average daily volume of 100 shares, the days-to-cover ratio is presently 232.0 days.
Separately, Stifel Nicolaus raised their target price on HLS Therapeutics from $35.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, July 21st.
Shares of OTCMKTS HLTRF remained flat at $$12.99 during midday trading on Wednesday. The business has a fifty day moving average of $13.18. HLS Therapeutics has a 1-year low of $11.06 and a 1-year high of $19.10.
HLS Therapeutics Company Profile
HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and Barbados. Its lead product is Clozaril, an atypical antipsychotic used in the treatment of schizophrenia.
Further Reading: What is channel trading?
Receive News & Ratings for HLS Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HLS Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.